Psoriasis
https://en.wikipedia.org/wiki/Psoriasis
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana. relevance score : -100.0%
References
Psoriasis 28846344 NIH
Phototherapy 33085287 NIH
Tumor Necrosis Factor Inhibitors 29494032 NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).
Kurapa kwakasiyana-siyana kunogona kubatsira kudzora zviratidzo. Mishonga iyi inosanganisira steroid creams, vitamin D3 cream, ultraviolet chiedza, uye immunosuppressive zvinodhaka, zvakadai semethotrexate. Inenge 75% yekubatanidzwa kweganda inovandudza nemafuta ega. Akasiyana-siyana biological immunological agents ari kugadzirwa kurapa psoriasis.
Psoriasis chirwere chinowanzoitika uye chirwere chinokanganisa 2-4% yevanhu. Varume nevakadzi vanobatwa nehuwandu hwakaenzana. Chirwere chinogona kutanga pazera ripi neripi, asi kazhinji chinotanga pakukura. Psoriatic arthritis inobata kusvika ku30% yevanhu vane psoriasis.
○ Kurapa ― OTC Mishonga
Chiedza chezuva chinogona kubatsira psoriasis nekuti kuratidzwa kwezuva kunokonzera shanduko yeimmunological muvarwere vane psoriasis. Chizoro chakapfava chehydrocortisone chinogona kubatsira kurapa mamwe maronda madiki e psoriasis.
#OTC steroid ointment
○ Kurapa
Psoriasis chirwere chisingaperi uye mishonga yakawanda yekurapa iri kuongororwa. Biologics ndiyo inoshanda zvakanyanya asi inodhura zvakanyanya.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)